Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors

被引：12

作者：

Li, Jian ^{[1
]}

Wang, Ming ^{[2
]}

Zhang, Bo ^{[3
]}

Wu, Xin ^{[4
]}

Lin, Tian-Long ^{[2
]}

Liu, Xiu-Feng ^{[5
]}

Zhou, Ye ^{[6
]}

Zhang, Xin-Hua ^{[7
]}

Xu, Hao ^{[8
]}

Shen, Li-Jing ^{[9
]}

Zou, Jing ^{[10
]}

Lu, Ping ^{[11
]}

Zhang, Dong ^{[12
]}

Gu, Wei-Jun ^{[13
]}

Zhang, Mei-Xia ^{[14
]}

Pan, Jian ^{[15
]}

Cao, Hui ^{[2
]}

机构：

[1] Peking Univ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Minist Educ Beijing, Beijing 100142, Peoples R China

[2] Shanghai Jiao Tong Univ, Reiji Hosp, Dept Gastrointestinal Surg, Sch Med, Shanghai 200127, Peoples R China

[3] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Sichuan, Peoples R China

[4] Gen Hosp Peoples Liberat Army, Dept Gen Surg, Beijing 100853, Peoples R China

[5] Chinese Peoples Liberat Anny 81st Hosp, Dept Oncol, Nanjing 210031, Jiangsu, Peoples R China

[6] Fudan Univ, Dept Gastr Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China

[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou 510080, Guangdong, Peoples R China

[8] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 320100, Jiangsu, Peoples R China

[9] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Hematol, Shanghai 200240, Peoples R China

[10] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Respirol, Shanghai 200240, Peoples R China

[11] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Dermatol, Shanghai 200240, Peoples R China

[12] Gen Hosp Peoples Liberat Army, Dept Nephrol, Beijing 100853, Peoples R China

[13] Gen Hosp Peoples Liberat Army, Dept Endocrinol, Beijing 100853, Peoples R China

[14] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China

[15] Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, Chengdu 610041, Sichuan, Peoples R China

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2018年 / 24卷 / 46期

关键词：

Side effects; Gastrointestinal stromal tumor; Tyrosine kinase inhibitors; Consensus guideline; China; CHRONIC MYELOID-LEUKEMIA; INTERSTITIAL LUNG-DISEASE; B-VIRUS REACTIVATION; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; SUNITINIB INDUCES HYPOTHYROIDISM; PERIORBITAL EDEMA SECONDARY; ACUTE HEPATIC-FAILURE; IMATINIB MESYLATE; CANCER-PATIENTS;

D O I：

10.3748/wjg.v24.i46.5189

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmology to consider the systemic clinical symptoms, molecular and cellular mechanisms, and treatment recommendations of GISTs. Here, we present the resultant evidence- and experience-based consensus to guide the management of TKI-associated side events in clinical practice.

引用

页码：5189 / 5202

页数：14

共 114 条

[1] Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis [J].